Burcak ERKOL, Fugen AKER, Zeynep Gamze KILICOGLU, Basak USTAALİOGLU, Tarık SALMAN

Serum β-human chorionic gonadotropin as a tumor marker for malignant mesothelioma

Peritoneal mesotheliomas are aggressive tumors arising from the peritoneal mesothelium. Tumor markers are biochemical substancesproduced by tumor cells due to the effect of malignant process. They can be used for screening, diagnosis, and predicting the prognosis. β-human chorionic β-human chorionic gonadotrophin (β-hCG), is a marker of germ cell tumors and trophoblastic diseases. In some reports, a relationship between β-hCG and other malignant diseases has been described. Hereby, we present a case of malignant peritoneal mesothelioma associated withelevated serum β-hCG levels. A 49-year-old man was admitted to the hospital with ascites. Peritoneal mesothelioma was diagnosed with peritoneal biopsy. During the treatment period, serum β-hCG levels were elevated together with disease progression and tissue samples stained positive for β-hCG. Rising levels of serum β-hCG due to disease progression can predict the response to treatment. If these levels were elevated at the beginning of the treatment, it may be a prognostic marker for peritoneal mesothelioma. Thus, β-hCG may be an important marker for prognosis or prediction of treatment for peritoneal mesothelioma patients.Keywords: Mesothelioma, Human chorionic gonadotrophin,Tumor marker

Anahtar Kelimeler:

Mezotelyoma, Human koryonik gonadotropin, Tümör belirteci

Serum β-human chorionic gonadotropin as a tumor marker for malignant mesothelioma

PDF

___

Raptopoulos V. Peritoneal mesothelioma. Crit Rev Diagn Imaging 1985;24:293-328.
Selvam NT, Elumalai P, Venkatakrishnan V, Damodarkumar S. Molecular markers in cancer diagnosis and management: A Review. JAppl Biol Sci 2011;5: 69-74. doi: 10.1002/iso.21787
Hussa RO. The clinical marker hCG. New York: Praeger, 1987.doi: 10.1038/modpathol.3800086
Berhil H, Chenna H, Nouni K, et al. Malignant mesothelioma of peritoneum: about a case with review of the literature. J Cancer Sci Ther 2012;4:235-6. doi:10.4172/1948-5956.1000147
Rich S, Presant CA, Meyer J, Stevens SC, Carr D. Human chorionic gonadrotropin and malignant mesothelioma. Cancer 1979; 43: 1457-62.
Okamoto H, Matsuno Y, Noguchi M, et al.Malignant pleural mesothelioma producing human chorionic gonadotropin. Am J Surg Pathol 1992;16:969-74.
Zimmerman R L, Fogt F. The β subunit of human chorionic gonadotropin lacks specificity for malignant cells in serous effusions. Modern Pathology 2004;17:701-4. doi:10.4172/1948-5956.1000147
Ugurman F, Gozu A, Akkalyoncu B, et al. Pleural fluid and serum β-hcg levels and pleural fluıd/serum β-hcg ratio for the discrimination of malignant and benign pleural effusions. Solunum Hastalıkları 2003;14: 186-92.doi: 10.4103/0975-8844.106192
Gibbs AR, Harach R, Wagner JC, Jasani B. Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma. Thorax 1985; 40: 91-5.
deBruijn HW, ten Hoor KA, Frans M, et al. Rising serum values of beta-subunit human chorionic gonadotrophin (hCG) in patients with progressive vulvar carcinomas. Br J Cancer 1997;75:1217-18.